News
Hosted on MSN1mon
Replimune down as FDA’s top cancer drug regulator reportedly intervened in drug rejection
Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top regulator of cancer drugs intervened during the review of the company’s lead asset ...
Replimune (NASDAQ:REPL) climbed more than 100% on Wednesday as Cantor Fitzgerald upgraded the cancer drug developer, citing a potential reversal of an FDA decision that rejected its lead drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback